These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 37395840)
1. Bioinspired thiazolo-[2,3-b] quinazolin-6-one derivatives as potent anti-cancer agents targeting EGFR: their biological evaluations and in silico assessment. Mir SA; Mohanta PP; Meher RK; Baitharu I; Behera AK; Raut S; Nayak B Mol Divers; 2023 Jul; ():. PubMed ID: 37395840 [TBL] [Abstract][Full Text] [Related]
2. In Silico and In Vitro Evaluations of Fluorophoric Thiazolo-[2,3-b]quinazolinones as Anti-cancer Agents Targeting EGFR-TKD. Mir SA; Dash GC; Meher RK; Mohanta PP; Chopdar KS; Mohapatra PK; Baitharu I; Behera AK; Raval MK; Nayak B Appl Biochem Biotechnol; 2022 Oct; 194(10):4292-4318. PubMed ID: 35366187 [TBL] [Abstract][Full Text] [Related]
3. Structural insights into conformational stability and binding of thiazolo-[2,3-b] quinazolinone derivatives with EGFR-TKD and Ahmad Mir S; Paramita Mohanta P; Kumar Meher R; Baitharu I; Kumar Raval M; Kumar Behera A; Nayak B Saudi J Biol Sci; 2022 Dec; 29(12):103478. PubMed ID: 36389208 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, molecular modeling, and biological evaluations of novel chalcone based 4-Nitroacetophenone derivatives as potent anticancer agents targeting EGFR-TKD. Mir SA; Murmu N; Meher RK; Baitharu I; Nayak B; Khan A; Khan MI; Abdulaal WH J Biomol Struct Dyn; 2024 Jan; ():1-16. PubMed ID: 38281944 [TBL] [Abstract][Full Text] [Related]
5. Exploring binding stability of hydroxy-3-(4-hydroxyphenyl)-5-(4-nitrophenyl)-5,5a,7,8,9,9a-hexahydrothiazolo[2,3-b] quinazolin-6-one with T790M/L858R EGFR-TKD. Mir SA; Nayak B J Biomol Struct Dyn; 2023 May; 41(8):3702-3716. PubMed ID: 35343861 [TBL] [Abstract][Full Text] [Related]
6. Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies. Kiriwan D; Seetaha S; Jiwacharoenchai N; Tabtimmai L; Sousa SF; Songtawee N; Choowongkomon K Chem Biol Drug Des; 2022 Mar; 99(3):456-469. PubMed ID: 34923743 [TBL] [Abstract][Full Text] [Related]
7. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis. Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320 [TBL] [Abstract][Full Text] [Related]
8. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies. Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960 [TBL] [Abstract][Full Text] [Related]
10. Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. Wassel MMS; Ammar YA; Elhag Ali GAM; Belal A; Mehany ABM; Ragab A Bioorg Chem; 2021 May; 110():104794. PubMed ID: 33735711 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of 6-(imidazo[1,2-a] pyridin-6-yl) quinazolin-4(3H)-one derivatives as potent anticancer agents by dual targeting Aurora kinase and ROR1. Fan Y; Zhang F; Xiong L; Su M; Luo F; Li M; Li Q; Zhong T; Yuan M; Xu Y; Mu S; Yang H Bioorg Chem; 2023 Jun; 135():106484. PubMed ID: 36963371 [TBL] [Abstract][Full Text] [Related]
12. New Niflumic Acid Derivatives as EGFR Inhibitors: Design, Synthesis, Yaseen YS; Mahmood AAR; Abbas AH; Shihab WA; Tahtamouni LH Med Chem; 2023; 19(5):445-459. PubMed ID: 36537605 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and evaluation of new quinazolin-4-one derivatives as apoptotic enhancers and autophagy inhibitors with potent antitumor activity. ElZahabi HSA; Nafie MS; Osman D; Elghazawy NH; Soliman DH; El-Helby AAH; Arafa RK Eur J Med Chem; 2021 Oct; 222():113609. PubMed ID: 34119830 [TBL] [Abstract][Full Text] [Related]
15. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives. Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348 [TBL] [Abstract][Full Text] [Related]
16. New phthalimide-based derivatives as EGFR-TK inhibitors: Synthesis, biological evaluation, and molecular modeling study. Mansour NI; El-Sayed SM; El-Gohary NS; Abdel-Aziz NI; El-Subbagh HI; Ghaly MA Bioorg Chem; 2022 Oct; 127():105966. PubMed ID: 35728294 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and Le Y; Gan Y; Fu Y; Liu J; Li W; Zou X; Zhou Z; Wang Z; Ouyang G; Yan L J Enzyme Inhib Med Chem; 2020 Dec; 35(1):555-564. PubMed ID: 31967481 [TBL] [Abstract][Full Text] [Related]
18. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights. Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies. El-Azab AS; Al-Dhfyan A; Abdel-Aziz AA; Abou-Zeid LA; Alkahtani HM; Al-Obaid AM; Al-Gendy MA J Enzyme Inhib Med Chem; 2017 Dec; 32(1):935-944. PubMed ID: 28718672 [TBL] [Abstract][Full Text] [Related]
20. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells. Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]